

Proposed Project Scope

Bevacizumab and lomustine for recurrent glioblastoma multiforme (GBM)

Date: March, 2023

Background and Rationale

CADTH received a request from public drug programs for a Non-Sponsored Reimbursement Review of bevacizumab and lomustine for recurrent glioblastoma multiforme.

Table I: Policy Questions

Item	Policy Question
1	Should bevacizumab and lomustine be publicly reimbursed for recurrent glioblastoma multiforme (GBM)?

Table II: Products Available in Canada

Product	Manufacturer
bevacizumab	BGP PHARMA ULC, HOFFMANN-LA ROCHE LIMITED, SAMSUNG BIOEPIS CO., LTD, APOTEX INC, AMGEN CANADA INC., PFIZER CANADA ULC
lomustine	BRISTOL-MYERS SQUIBB CANADA

Project Description

Table III: Project Scope

Criteria	Description
Population	Adult patients with glioblastoma after relapse or disease progression
Intervention(s)	bevacizumab 10mg/kg every 2 weeks in combination with other agents (e.g. lomustine, carmustine, carboplatin, etoposide, irinotecan, nimustine, fotemustine, temozolomide, vorinostat, dasatinib, everolimus, panobinostat, sorafenib, temsirolimus)
Comparators	Placebo or various agents without bevacizumab (e.g. lomustine, carmustine, carboplatin, etoposide, irinotecan, nimustine, fotemustine, temozolomide, vorinostat, dasatinib, everolimus, panobinostat, sorafenib, temsirolimus)
Outcomes	Progression free survival (PFS), overall survival (OS), objective response rate (ORR), duration of response (DOR), health-related quality of life, harms (adverse events, serious adverse events, death)

Table IV: Research Questions

Item	Policy Question
1	What is the effectiveness of bevacizumab and lomustine for recurrent glioblastoma multiforme?
2	What are the harms associated with bevacizumab and lomustine for recurrent glioblastoma multiforme?
3	What is the expected cost of bevacizumab and lomustine for recurrent glioblastoma multiforme vs. other reimbursed regimes?

Key Project and Protocol Components

This project will follow the [Procedures for Non-Sponsored Reimbursement Reviews](#).

Status of the Document

This proposed project scope is being posted for information.